Antiretroviral drugs for AIDS

Lancet

Volumn 348, Issue 9030, 1996, Pages 800-803

  Lipsky, James J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROLITHIASIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030596902     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)12333-4     Document Type: Review

References (45)

1. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124: 984-94.
2. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993; 328: 1686-95.
3. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
4. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275: 1329-34.
5. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection Lancet 1994; 343: 871-81.
6. Volberding PA, Lagakos SW, Grimes JA, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401-07.
7. Kinloch-Löes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-13.
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-26.
9. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
10. Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-54.
11. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-79.
12. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-31.
13. Ho DD. Viral counts count in HIV infection. Science 1996; 272: 1124-25.
14. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
15. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-08.
16. Domingo E, Escarmis C, Sevilla N, et al. Basic concepts in RNA virus evolution. FASEB 1996; 10: 859-64.
17. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92: 2398-402.
18. Sande MA, Carpenter CCJ, Cobbs CG, Homes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients: recommendations from state-of-the-art conference. JAMA 1993; 270: 2583-89.
19. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124: 1086-87.
20. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-51.
21. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333: 1662-69.
22. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-99.
23. Wainberg MA, Drosopoulos WX, Salomon H, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271: 1282-85.
24. Chow Y-K, Hirsch MS, Merrill DP, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993; 361: 650-54.
25. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.
26. Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomon L. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center, JAMA 1996; 275: 1504-06.
27. Morrow CD, Park J, Wakefield JK. Viral gene products and replication of the human immunodeficiency type 1 virus. Am J Physiol 1994; 266: C1135-56.
28. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-55.
29. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-39.
30. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
31. Anon. AIDS. Prescribers Lett. 3:1996;35.
32. Anon. New drugs for HIV infection. Med Lett Drugs Ther. 38:1996;35-38.
33. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-93.
34. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 1019-30.
35. Reichman RC, Morse GD, Demeter L.M.et al. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. J Infect Dis. 171:1995;297-304.
36. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270: 1197-99.
37. Mizrachi Y, Rubinstein A, Harish Z, Biegon A, Anderson WR, Brewster ME. Improved brain delivery and in vitro activity of zidovudine through the use of a redox chemical delivery system. AIDS 1995; 9: 153-58.
38. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 1994; 170: 1394-403.
39. Kilby JM, Saag MS. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infect Agents Dis 1994; 3: 313-23.
40. Rice WG, Supko JG, Malspeis L, et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1995; 270: 1194-97.
41. Baier M, Werner A, Bannert N, Meztner K, Kurth R HIV suppression by interleukin-16. Nature. 378:1995;563.
42. +T cells. Science 1995; 270: 1811-16.
43. Balter M A second coreceptor for HIV in early stages of infection. Science. 272:1996;1740.
44. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
45. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patient's survival. N Engl J Med 1996; 334: 701-06.